CYP17A1 and myeloid sarcoma: Our current data also suggested an absence of specific enzyme blocks in the cortisol pathway associated with anti-MS treatment (unaffected MS treatment CYP17A1, HSD3B, CYP11B1, and HSD11B1) activities.